Any takers so far.
I knew their days were numbered when they decided against HCV total core antigen and moving forward with a dedicated molecular effort. Starving the business has killed it.
At least the dry chemistries have a lot of supporters because of the calibration stability and has the least susceptibility to common interferences, such as lipemia, hemolysis, and icterus. The cartridges wiht disposable slides have made both potentiometric, colorimetric, and rate assays very attractive for small to middle sized laboratories. Once a lab exceeded a certain volume of testing, it becomes difficult to store all of the frozen and refrigerated cartridges and remember to take out an adequate number of slides to equilibrate at room temperature before the analyzer runs out of slides.
Yes, the wet side is very slow and there have been nothing new on the IA side...it's just a bigger ECI.
I would say OCD is very valuable in the sense it does have the intellectual property for the infectious disease assays. Mechanically, the 5,1 and 5600 has not been as reliable as the Vitros 950's.
What you get if you dump the best I-A enhanced chemiluminescent R&D group going. And no new assays. Big surprise.
Cathie-the-Terminator deserved a raise for that one.
And letting a group from what was a photographic company develop an Immuno-Assay system was somewhat strange and a million miles from its clin-chem business. Individual wells? Bonkers. Especially as a customer cannot develop custom assays as he could with Amerlite and let the company take it to market.
Kodak couldn't even make a decent photocopier but had to buy in from Cannon. Raritan had to buy in its instruments.
Ramming I-A and clin-chem into one instrument system was like what the monkey said to the cat: "A tight fit but its gonna go in".
Surprised O-CD has lasted this long.
It is sad to see what is occurring with Ortho. Abbott has HIV combo whilst Ortho, though they have spoken of it, still have not brought it to market. This is probably why Abbott is gaining. Why Ortho is late with HIV combo is a bit of a mystery as at one time they had a very formidable Infectious Disease portfolio. My guess is a reduction in funding/staffing via J&J looking to unload them thus leading to delays.
The 5,1 had a reasonable design yet from the labs I have seen it in the techs stated that the wet side seemed slow. I thought they would have improved the wet side with the 5600. We wanted one to run drug screens which on the 5600 runs on the wet side. I think they call it a tip assay. We like the dry slide assay stability. The rep said the 5600 was designed for random access not batching. When I explained that is how our clinics send in DAB urines, in groups, the rep stated we would have to not run them as a batch. ???? Who gave them lab imput on the design?
I don't think anyone is interested in buying them. They are losing a significant amount of market share, especially in the hepatitis/HIV ab testing area. I think Abbott is making big strides in gaining market share from OCD on that end.
The 5,1's are being replaced with Olympus in the Kaiser system and the 5600's are performing poorly. Integrating an IA system into their chemistry analyzer was a bad idea especially since their IA system was prone to jams with stuck RV's if it was pushed too hard. Once you have to open up the incubator, all of those tests will have to be repeated at your cost.
Unfortunately, what are the options? Crappy Vista's or old Synchron's?
I would think Danaher would buy part of the company only to round out their IA menu with Hepatitis/HIV ab testing.
No news is good news? Sell-off or other disposal rumors all rubbish?
nothing, as usual
Were not on euromedlab
More information about formatting options